FDA Announces Submission for OMB Review of Financial Disclosure Requirement for Clinical Investigators

Summary

The Food and Drug Administration (FDA) is announcing that the proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995, seeking public comment on the requirement for financial disclosure by clinical investigators.